Idiopathic Choroidal Neovascularization Clinical Trial
Official title:
Intravitreal Conbercept for Idiopathic Choroidal Neovascularization
The purpose of this study is to evaluate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy as primary treatment for ICNV.
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02257502 -
Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients
|
Phase 2 |